معالجة الملتوية البوابية دراسة مقارنة بين أربع بروتوكولات علاجية باستخدام معالجة ثلاثية
Abstract
منذ اكتشاف جرثومة الملتوية البوابية ومسؤوليتها عن العديد من الأمراض وخاصة تلك المتعلقة بالمعدة بدءاً من عسر الهضم... التهاب المعدة... القرحة وانتهاء بالأورام الخبيثة المعدية والبحث عن معالجة فعالة للتخلص من هذه الجرثومة بغية الشفاء من المرض والحد من انتشاره متواصل. ويستمر عدد الأدوية المستخدمة والبروتوكولات الدوائية المتبعة في تزايد مستمر.
إن الهدف من هذه الدراسة هو تحديد بدقه البرتوكول الأنجح في الشفاء من هذه الجرثومه باستخدام عقار مثبط لمضخة البروتون مع نوعين من الصادات الحيوية حيث عولج 257 مريضاًًًً ثبت لديهم الإصابة والأنتان المعدي بالملتوية البوابية توزعوا على الشكل التالي 138 ذكراً و119 أنثى تراوحت أعمارهم بين 17 – 72 سنه وقسموا إلى أربع مجموعات تلقوا أربع مجموعات دوائية مختلفة أظهرت فعالية متفاوته في العلاج حيث كان أفضلها المجموعة التي حوت مركب Tinidazol سواء مع مركب كلاريترومايسين أو أموكسسسيلين ويمكن اعتباره العقار المفضل.
Since the discovery of Hilecobacter pylori and its responsibility for multi diseases especially those which are related to stomach, for example: dyspepsia ,gastritis, ulcer and malignant gastric tumers, and the research for effective treatment for getting rid of this organ in order to recover from diseases and prevent its spreading, The researches continue and the number of drugs used and the medical protocols have been increasing.
The aim of this study is the exact detection of the best protocol for iriadicatian of Hileco bacter pylori by using a drug. Includiug inhibitor of proton's pump, and two types of anti biotics.
257 patients who had an infection of stomach with hilecobacter pylori were divided as the following: 138 male, 119 female and their ages ranged between 17-72 years.
The patients were divided into four groups, they were treated by four different medical protocols wich were affective in the treatment.
The best protocols, which contains Tinidazol with claritromycin or Amoxycillin, so we can consider it as drug of choice.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series
Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in Tishreen University Journal for Research and Scientific Studies - Health Sciences Series . The Readers have the right to send, print and subscribe to the initial version of the article, and the title of Tishreen University Journal for Research and Scientific Studies - Health Sciences Series Publisher
journal uses a CC BY-NC-SA license which mean
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.